← Back to Search

PET MRI for Predicting Liver Cancer Recurrence (PETMRIinHCC Trial)

N/A
Waitlist Available
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults (age ≥ 18-years old)
Histological or radiological diagnosis of HCC (AASLD guidelines)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is studying how well 18F-FDG PET/MRI works in predicting HCC recurrence after liver transplant.

Who is the study for?
This trial is for adults over 18 with a diagnosis of early-stage Hepatocellular Carcinoma (HCC) who are listed for liver transplantation at UHN. Participants must be willing to give informed consent and able to undergo PET/MRI scans. They should also be enrolled in a ctDNA study.
What is being tested?
The trial is testing the use of an imaging technique called 18F-FDG PET/MRI to predict HCC recurrence after liver transplantation. It aims to see if this method can indicate tumor behavior and link it with circulating tumor DNA in the blood, potentially influencing transplant eligibility criteria.
What are the potential side effects?
Since the intervention involves only non-invasive imaging techniques like PET and MRI, there are minimal side effects which may include discomfort during scanning or reactions related to contrast agents used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
My liver cancer diagnosis was confirmed by lab tests or scans.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
18F-FDG PET/MRI results can identify aggressive HCC behavior and recurrence post transplant
Secondary study objectives
18F-FDG PET/MRI are related to presence of circulating tumor DNA in plasma
18F-FDG PET/MRI can predict HCC's poor tumoral differentiation

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: PET MRI ArmExperimental Treatment1 Intervention
Patient enrolled in the study will have a PET MRI exam scheduled before transplant

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor
1,531 Previous Clinical Trials
504,302 Total Patients Enrolled
3 Trials studying Liver Cancer
51 Patients Enrolled for Liver Cancer
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top